Patients with recessive dystrophic epidermolysis bullosa (RDEB) suffer from acute and chronic post-bullous wounds along with impaired skin healing. These issues are attributed not only to mucocutaneous fragility and abnormal healing directly related to quantitative and/or qualitative constitutional abnormalities of collagen VII but also to a contingent cutaneous and systemic inflammatory component. This inflammatory aspect contributes to the perpetuation of skin lesions and delayed healing. Our primary objective is to define the systemic immunological/inflammatory signature of patients with RDEB with an aim to develop a strategy that involves using stem cells with high immunomodulatory/anti-inflammatory capacity such as allogeneic placental stem cells (WJ-MSCs and trophoblasts).

Inclusion Criteria:

EBDR patients :

• Patients aged 18 to 80 years old
• Clinically, histologically, and/or genetically confirmed intermediate, reversed or generalized, moderate to severe EBDR

Healthy controls :

• Adults aged 18 to 80 years old
• PBMC healthy donors: subjects who have donated blood to the EFS according to the indication criteria who have consented to the use of their samples for research purposes.
• Healthy skin biopsy donors: subjects undergoing abdominoplasty scheduled in plastic surgery and who have given their consent for the collection of a skin biopsy from post-operative abdominoplasty skin remnants.
• Healthy donors of bandages soiled with exudates from cutaneous wounds: subject consulting a plastic surgery department as part of their usual post-operative follow-up, who have given their consent for the collection of one of their dressings during their usual during their usual renewal.

For all subjects :

• Free, informed, written consent, signed by the person and the investigator no later than the day of inclusion and before any examination carried out as part of the study.
• Person affiliated or benefiting from a social security scheme

Exclusion Criteria:

EBDR patients :

• EBH with no definite diagnosis or other than EBDR intermediate, reversed or generalized
• Systemic anti-inflammatory or immunosuppressive therapy for less than one month
• Refusal of skin biopsy

Healthy controls :

• Acute or chronic systemic or cutaneous inflammatory disease at the time of sampling
• Current immunosuppressive anti-inflammatory treatment in the month prior to sampling

For all subjects:

• Persons under guardianship or curatorship, or deprived of their liberty by judicial or administrative decision
• Patients receiving State Medical Aid
• Pregnant or breast-feeding women

Patients with recessive dystrophic epidermolysis bullosa and healthy control patients